Bristol-Myers Squibb Quarterly Balance Sheet
NYSE: BMYHealthcareDrug Manufacturers - GeneralUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bristol-Myers Squibb financial position
As of Jun 30, 2026, Bristol-Myers Squibb reported total assets of $87.63 billion, down 7.4% from a year earlier against total liabilities of $65.31 billion. Shareholders' equity stood at $22.32 billion, or 25.5% of assets. The company held $8.72 billion in cash and equivalents against $43.12 billion of debt, a net debt position of $34.40 billion.
The current ratio (current assets divided by current liabilities) was 1.53, meaning short-term assets cover obligations due within a year. Debt-to-equity was 1.93.
Summary generated from market data by MetaCap's automated system. Methodology
Bristol-Myers Squibb balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 8.72B | 9.57B | 10.21B | 15.73B | 12.60B | 10.88B | 10.35B | 7.89B | 6.29B | 9.33B | 11.46B | 7.51B |
| Short-Term Investments | 2.35B | 912.00M | 464.00M | 776.00M | 1.00B | 907.00M | 513.00M | 204.00M | 360.00M | 340.00M | 816.00M | 171.00M |
| Receivables | 9.08B | 7.95B | 9.59B | 9.62B | 9.71B | 9.06B | 9.01B | 9.32B | 9.75B | 8.83B | 8.88B | 8.41B |
| Inventory | 2.74B | 2.76B | 2.69B | 2.76B | 2.74B | 2.67B | 2.56B | 3.33B | 3.08B | 2.98B | 2.66B | 2.44B |
| Total Current Assets | 28.58B | 27.21B | 29.39B | 35.63B | 33.22B | 30.78B | 29.78B | 28.07B | 26.89B | 28.67B | 31.77B | 27.63B |
| Property, Plant & Equipment | 7.79B | 7.66B | 7.54B | 7.35B | 7.37B | 7.21B | 7.14B | 6.90B | 6.84B | 6.75B | 6.65B | 6.48B |
| Goodwill | 21.74B | 21.74B | 21.75B | 21.75B | 21.78B | 21.74B | 21.72B | 21.75B | 21.73B | 21.74B | 21.17B | 21.15B |
| Intangible Assets | 17.39B | 18.24B | 19.10B | 20.46B | 21.38B | 22.49B | 23.31B | 26.96B | 29.43B | 32.76B | 27.07B | 28.95B |
| Long-Term Investments | 397.00M | 366.00M | 396.00M | 406.00M | 346.00M | 344.00M | 320.00M | 324.00M | 357.00M | 367.00M | 364.00M | — |
| Total Assets | 87.63B | 86.48B | 90.04B | 96.89B | 94.68B | 92.43B | 92.60B | 93.67B | 94.65B | 99.03B | 95.16B | 91.26B |
| Accounts Payable | 4.16B | 4.23B | 3.58B | 4.29B | 5.43B | 4.00B | 3.60B | 3.47B | 3.75B | 3.54B | 3.26B | 2.81B |
| Short-Term Debt | 1.03B | 2.31B | 2.26B | 4.51B | 4.71B | 3.55B | 2.05B | 1.08B | 3.53B | 6.19B | 3.12B | 5.47B |
| Total Current Liabilities | 18.66B | 19.16B | 23.42B | 28.14B | 27.53B | 24.07B | 23.77B | 22.64B | 23.27B | 25.82B | 22.26B | 23.46B |
| Long-Term Debt | 42.09B | 42.15B | 42.85B | 44.47B | 44.47B | 46.16B | 47.60B | 48.67B | 48.86B | 49.49B | 36.65B | 32.14B |
| Total Liabilities | 65.31B | 66.37B | 71.53B | 78.29B | 77.19B | 74.98B | 76.22B | 76.47B | 77.58B | 82.48B | 65.67B | 62.20B |
| Shareholders' Equity | 22.32B | 20.07B | 18.47B | 18.55B | 17.43B | 17.39B | 16.34B | 17.14B | 17.02B | 16.49B | 29.43B | 29.00B |
| Retained Earnings | 20.32B | 18.29B | 16.90B | 17.09B | 16.15B | 16.11B | 14.91B | 16.10B | 16.10B | 15.64B | 28.77B | 28.22B |
| Total Debt | 43.12B | 44.46B | 45.11B | 48.98B | 49.19B | 49.71B | 49.65B | 49.75B | 52.39B | 55.68B | 39.77B | 37.60B |
| Net Cash (Debt) | -32.05B | -33.97B | -34.44B | -32.48B | -35.58B | -37.93B | -38.79B | -41.66B | -45.74B | -46.01B | -27.49B | -29.92B |
This table shows 12 quarterly periods of Bristol-Myers Squibb's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow BMY's reporting calendar. What is a balance sheet?